Valeant And AstraZeneca To Partner On Brodalumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
September 2, 2015 10:23 AM EDTBMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
